ImmuPharma (IMM) Competitors

ImmuPharma logo
GBX 2.90 +0.49 (+20.37%)
As of 11:58 AM Eastern

IMM vs. REDX, FARN, ETX, HEMO, and POLB

Should you buy ImmuPharma stock or one of its competitors? ImmuPharma's main competitors and comparable companies include Redx Pharma (REDX), Faron Pharmaceuticals Oy (FARN), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), and Poolbeg Pharma (POLB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmuPharma compare to Redx Pharma?

Redx Pharma (LON:REDX) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

ImmuPharma has a net margin of 3,519.56% compared to Redx Pharma's net margin of 0.00%. Redx Pharma's return on equity of -180.80% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Redx PharmaN/A -180.80% -43.95%
ImmuPharma 3,519.56%-559.87%-43.00%

Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.017, meaning that its stock price is 202% more volatile than the broader market.

72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 18.4% of Redx Pharma shares are held by company insiders. Comparatively, 6.2% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmuPharma has lower revenue, but higher earnings than Redx Pharma. ImmuPharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A
ImmuPharmaN/AN/A-£2.51M-£0.83N/A

In the previous week, Redx Pharma had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Redx Pharma and 0 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.00 beat Redx Pharma's score of -0.45 indicating that ImmuPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Redx Pharma Neutral
ImmuPharma Neutral

Summary

Redx Pharma and ImmuPharma tied by winning 6 of the 12 factors compared between the two stocks.

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A
ImmuPharmaN/AN/A-£2.51M-£0.83N/A

3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 6.2% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for ImmuPharma. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
ImmuPharma Neutral

ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 476.49% -70.00%
ImmuPharma 3,519.56%-559.87%-43.00%

Faron Pharmaceuticals Oy has a beta of 1.116, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.017, suggesting that its stock price is 202% more volatile than the broader market.

Summary

ImmuPharma beats Faron Pharmaceuticals Oy on 7 of the 10 factors compared between the two stocks.

How does ImmuPharma compare to e-therapeutics?

e-therapeutics (LON:ETX) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

ImmuPharma has lower revenue, but higher earnings than e-therapeutics. ImmuPharma is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
e-therapeutics£295K0.00-£10.06M-£0.02N/A
ImmuPharmaN/AN/A-£2.51M-£0.83N/A

26.5% of e-therapeutics shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 59.4% of e-therapeutics shares are held by insiders. Comparatively, 6.2% of ImmuPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.

Company Overall Sentiment
e-therapeutics Neutral
ImmuPharma Neutral

e-therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.017, suggesting that its stock price is 202% more volatile than the broader market.

ImmuPharma has a net margin of 3,519.56% compared to e-therapeutics' net margin of 0.00%. e-therapeutics' return on equity of -38.75% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
e-therapeuticsN/A -38.75% -29.10%
ImmuPharma 3,519.56%-559.87%-43.00%

Summary

e-therapeutics beats ImmuPharma on 6 of the 10 factors compared between the two stocks.

How does ImmuPharma compare to Hemogenyx Pharmaceuticals?

ImmuPharma (LON:IMM) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
ImmuPharma Neutral
Hemogenyx Pharmaceuticals Neutral

ImmuPharma has a beta of 3.017, indicating that its stock price is 202% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its stock price is 49% more volatile than the broader market.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.83N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A

ImmuPharma has a net margin of 3,519.56% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Hemogenyx Pharmaceuticals' return on equity of -409.57% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -559.87% -43.00%
Hemogenyx Pharmaceuticals N/A -409.57%-37.79%

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 6.2% of ImmuPharma shares are held by company insiders. Comparatively, 0.9% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ImmuPharma beats Hemogenyx Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does ImmuPharma compare to Poolbeg Pharma?

ImmuPharma (LON:IMM) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

ImmuPharma has a beta of 3.017, indicating that its share price is 202% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.841, indicating that its share price is 84% more volatile than the broader market.

In the previous week, Poolbeg Pharma had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for ImmuPharma. Poolbeg Pharma's average media sentiment score of 0.75 beat ImmuPharma's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
ImmuPharma Neutral
Poolbeg Pharma Positive

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 4.5% of Poolbeg Pharma shares are held by institutional investors. 6.2% of ImmuPharma shares are held by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.83N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.79N/A

ImmuPharma has a net margin of 3,519.56% compared to Poolbeg Pharma's net margin of 0.00%. Poolbeg Pharma's return on equity of -71.28% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -559.87% -43.00%
Poolbeg Pharma N/A -71.28%-21.33%

Summary

Poolbeg Pharma beats ImmuPharma on 6 of the 11 factors compared between the two stocks.

Get ImmuPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMM vs. The Competition

MetricImmuPharmaBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£18.10M£3.92B£7.42B£2.68B
Dividend Yield0.77%3.64%2.48%5.11%
P/E Ratio-3.4923.5332.4522.78
Price / SalesN/A15.598.084.91
Price / Cash20.5022.6520.7220.23
Price / Book4.494.124.312.40
Net Income-£2.51M-£24.03M£3.51B£5.88B
7 Day Performance2.66%-9.57%-7.89%-3.52%
1 Month Performance-29.39%-13.67%-10.43%-4.94%
1 Year Performance-69.20%-6.29%-2.77%4.49%

ImmuPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMM
ImmuPharma
N/AGBX 2.90
+20.4%
N/A-73.6%£18.10MN/AN/A13
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
FARN
Faron Pharmaceuticals Oy
N/AGBX 28.30
-5.7%
N/A-84.1%£57.42MN/AN/A34
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 690.92
+10.7%
N/A-24.7%£47.65MN/AN/A14

Related Companies and Tools


This page (LON:IMM) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners